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1  | INTRODUC TION
Depression is common in the general population and has a large impact 
on functioning in daily life (Wittchen et al., 2011). Compared to the 
general population, even higher numbers of depression and depressive 
symptoms are found in the population of adults with intellectual disabil-
ities (Cooper, Smiley, Morrison, Williamson, & Allan, 2007; Hermans, 
Beekman, & Evenhuis, 2013). Despite the large number of adults with 
intellectual disabilities and depressive symptoms, treatment options, 
especially for those with severe intellectual disabilities, are scarce 
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Abstract
Background: Although a large number of adults with intellectual disabilities have de-
pressive symptoms, non-pharmacological treatments are scarce. The present authors 
investigated whether bright light therapy (BLT) is effective in decreasing depressive 
symptoms compared to care as usual.
Methods: This multicentre randomized controlled trial consisted of three study 
groups (10,000 lux BLT, dim light BLT and a no-BLT group). Participants received 
BLT for 30 min in the morning (14 consecutive days), additional to their regular care. 
Primary outcome was as follows: depressive symptoms measured with the ADAMS 
Depressive Mood subscale 1 week after the end of BLT (same time period in the no-
BLT group).
Results: Forty-one participants were included in our trial. In both BLT groups, a sig-
nificant decrease in depressive symptoms was seen. No significant differences were 
found between 10,000 lux BLT and no-BLT (p = .199) and no significant differences 
between dim light BLT and no-BLT (p = .451). A minimum amount of side effects and 
no adverse events were reported.
Conclusions: In both BLT interventions, a decrease in depressive symptoms was seen. 
With 10,000 lux BLT, depressive symptoms decreased even below the clinical cut-off 
point, which makes BLT a promising intervention for clinical practice.
K E Y W O R D S
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(Hamers, Festen, & Hermans, 2018). Some adults with mild or mod-
erate intellectual disabilities and without major verbal limitations may 
benefit from psychological interventions, for example cognitive be-
havioural therapy (CBT) (Vereenooghe & Langdon, 2013), but a large 
part of adults with intellectual disabilities and depressive symptoms 
get pharmacological treatment or no treatment at all. Pharmacological 
side effects, high numbers of polypharmacy, the lack of non-pharma-
cological interventions for those with severe intellectual disabilities, 
together with the high prevalence of depressive symptoms in adults 
with intellectual disabilities, make investigating other non-pharmaco-
logical interventions extremely important.
1.1 | Bright light therapy
In the general population, bright light therapy (BLT) is broadly 
studied and used in clinical practice to treat seasonal affective 
disorder and non-seasonal depression (Even, Schroder, Friedman, 
& Rouillon, 2008; Golden et al., 2005; Lieverse et al., 2011; 
Martiny, 2004; Nussbaumer et al., 2015; Tuunainen, Kripke, & 
Endo, 2004). The working mechanism is not fully understood, but it 
is suggested that disturbances in the circadian rhythms are involved 
(Germain & Kupfer, 2008; Monteleone, Martiadis, & Maj, 2011; 
Wirz-Justice, 2006). Our main biological clock, which controls our 
circadian rhythms, is situated in the hypothalamus in the supra-
chiasmatic nucleus (SCN). Retinal light input is the main influencer 
of the biological clock (Wirz-Justice, 2006). Neural pathways from 
the SCN lead to the pineal gland where melatonin is produced. In 
this way, light can influence the secretion of melatonin: when the 
amount of light increases, the production of the hormone melatonin 
is decreased (Griefahn, Kuenemund, & Robens, 2006). The effect 
of BLT is comparable to those of pharmacological interventions to 
decrease depressive symptoms (Golden et al., 2005), and BLT can 
even be more effective when combined with antidepressants (Lam 
et al., 2016). Besides, BLT seems to be a safe intervention without 
major side effects (Brouwer et al., 2017; Kogan & Guilford, 1998; 
Meesters & Letsch, 1998).
Unfortunately, the results of BLT studies in the general pop-
ulation cannot be generalized to the population of adults with 
intellectual disabilities, because many adults with intellectual dis-
abilities have some kind of brain damage that might interfere with 
the above-mentioned neural pathways, for example congenital brain 
damage, progressive brain damage or damage caused by traumatic 
injury. Furthermore, a large amount of adults with intellectual dis-
abilities are care-dependent and have physical and/or mobility 
problems. Therefore, it is possible that they benefit less from direct 
daylight because they do not spend the same amount of time outside 
compared to the general adult population.
In the intellectual disability population, BLT did not get 
much attention yet. Since 1998, some case reports were pub-
lished (Altabet, Neumann, & Watson-Johnston, 2002; Cooke & 
Thompson, 1998; Tsiouris, 2007). These first explorations of BLT 
in the intellectual disability population showed promising results. 
However, systematic report of the results and control groups were 
lacking. A feasibility study in the Netherlands showed that BLT 
is a feasible intervention for adults with intellectual disabilities. 
Besides, they found a decrease in depressive symptoms after 
BLT in almost all patients, and in nearly half of the sample, a clin-
ical relevant improvement was found (Hermans, Soerokromo, & 
Evenhuis, 2017). As larger studies with control groups are needed 
to expand the knowledge of the effect of BLT in the intellectual 
disability population, the primary objective of our study was to in-
vestigate whether BLT is effective in decreasing depressive symp-
toms in two BLT intervention groups compared to no-BLT (control 
group). Our secondary objective was to examine whether there is 
a significant difference in the effect of BLT between the two BLT 
intervention groups. Besides, we examined whether the effect of 
BLT is still visible 4 weeks after the end of BLT.
2  | METHOD
2.1 | Participants
Potential participants were recruited in three large care provider 
centres in the Netherlands that are part of the Healthy Ageing and 
Intellectual Disabilities Consort (HA-ID Consort). Physicians, psy-
chologists and behavioural scientists of the care provider centres 
selected potential participants and decided whether a potential par-
ticipant was able to understand the information of the study and to 
make the decision to give informed consent for participation. If the 
participant was not able to decide, the legal guardian was informed 
and gave written consent. Recruitment and inclusion of the partici-
pants started in May 2015 and ended in September 2017. The data 
collection ended in November 2017.
2.2 | Inclusion and exclusion criteria
Adults with intellectual disabilities (IQ ≤ 70) and with depressive 
symptoms were included in this study. To be included, a minimum 
score of 14 (clinical cut-off point) was needed on the Depressive 
Mood subscale of the Dutch version of the Anxiety, Depression And 
Mood Scale (ADAMS; range 0–39) (Hamers, van Ool, et al., 2018; 
Hermans & Evenhuis, 2013). Exclusion criteria were checked by a 
physician and behavioural scientist who were involved with the care 
of the participant. Exclusion criteria were as follows: a diagnosis of 
bipolar disorder, prepartum and/or post-partum depression, demen-
tia, current delirium, hypomanic, current manic or psychotic episode, 
current suicidal behaviour or suicidal expressions and aphakia (the 
lens of the eye is missing). In addition, because of possible side ef-
fects in combination with BLT, the physician excluded participants 
who used specific photosensitizing medications and had recent eye 
surgery or certain diseases, for example porphyria and urticaria sola-
ris. Previous BLT sessions must have ended more than 4 weeks prior 
to the inclusion.
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2.3 | Ethical regulation and trial registration
Written informed consent was retrieved from each participant or 
from their legal guardian if the participant was not able to decide 
for himself due to the intellectual disabilities. The study did not in-
terfere with the usual care and treatment of the participants. Ethical 
approval for all three care provider centres was given by the Ethics 
Committee of the Erasmus University Medical Centre Rotterdam 
in the Netherlands. Guidelines of the Declaration of Helsinki (64th 
WMA General Assembly, October 2013) were followed. Besides, 
this study is registered prior to the start of the study (NTR number: 
NTR5162) and CONSORT guidelines regarding Randomised Trials 
of Nonpharmacologic Treatments were followed (Boutron, Altman, 
Moher, Schulz, & Ravaud, 2017).
2.4 | Study design
2.4.1 | Randomization and masking
We conducted a multicentre randomized controlled trial (RCT) with 
three study groups to investigate the effect of BLT in adults with 
depressive symptoms. Block stratification was used to ensure that 
participants were properly distributed over the three study groups 
within each of the three participating centres. Block stratification 
was performed by a computerized program developed by an inde-
pendent data manager. One researcher (PH) enrolled the partici-
pants and used the outcomes of the digital randomization to assign 
the participants to the right group. To ensure blinding of the re-
searchers, lightboxes were coded before the start of the study by 
an independent researcher. Furthermore, the researchers and the 
professional staff were not informed about which type of lightbox 
was distributed to the participants. The participants and their pro-
fessional caregivers were not blinded and were told that two light-
boxes with different amount of lux were tested in the current study. 
They were instructed not to share details of the lightboxes and the 
amount of lux with the researchers. Participants living together at 
the same residence did not get BLT at the same time. When data col-
lection was finished, the blinding was broken. No changes to meth-
ods were made after trial commencement.
2.4.2 | Sample size
Prior to this study, the ideal sample size was calculated based on 
a clinically relevant difference of four points decrease on the 
Depressive Mood subscale of the Anxiety, Depression And Mood 
Scale (ADAMS) (Hermans & Evenhuis, 2013; Hermans, Jelluma, van 
der Pas, & Evenhuis, 2012). Details of the sample size calculation 
are previously published (Hamers, Evenhuis, & Hermans, 2017). Our 
aim was to include at least 57 participants in each group. Hence, 
a maximum of 171 participants would be included in our study. 
Unfortunately, after an inclusion period of almost two and a half 
years (May 2015–September 2017), the intended sample size was 
not reached. A large screening with the inclusion criteria of this 
study among adults with intellectual disabilities (>1,000 participants) 
in the three participating care provider centres from October 2016 
to March 2017 revealed some potential participants, but did not 
give enough perspective to extent the inclusion period longer than 
September 2017. Detailed information of our study protocol and the 
different obstacles we faced in this study are published previously 
(Hamers et al., 2017).
2.4.3 | Intervention
Two intervention groups (10,000 lux and a dim light condition) 
were used in this study. The dim light condition can be considered 
as a “placebo” condition of an BLT intervention. We compared the 
results of the 10,000 lux intervention with the results of the dim 
light condition, to study a possible placebo effect. In group I, par-
ticipants received BLT with a 10,000 lux bright white UV-filtered 
lightbox (Philips Energy lightbox, type HF3319), additional to their 
care as usual. Participants in group II received BLT with a bright 
white lightbox with on average 317 lux, additional to their care as 
usual. In group II, we used the same lightbox as in group I, but a LEE 
filter (no. 299) was installed. This heat-resistant filter did not change 
the colour of the light. On the outside, the two lightboxes looked 
the same when they were turned off. The participants in group III 
got no-BLT only care as usual (control group). Participants in the 
two intervention groups received 30-min BLT in the morning as 
early as possible after wake up (at least before 12 a.m.), for a period 
of 14 consecutive days. Usually, BLT was given during breakfast. 
Besides oral information, a detailed BLT manual with pictograms 
was given to the participant and the professional caregiver before 
the start of the intervention. The professional caregivers were 
asked to report adherence in a daily log. The distance between 
the participant and the lightbox was 20 cm (tape measures were 
distributed). A distance of 30 cm was only allowed when the 20 cm 
distance was not possible, for example because of wheelchair use. 
When a 30 cm distance was used, BLT was extended with 30 min 
per day according to the manual of the lightbox. The treatment 
distances in group I and group II were the same. The amount of 
lux of all lightboxes was measured by the Medical Technology 
Department of the Erasmus University Medical Center Rotterdam 
in the Netherlands with the use of a lux metre (Konica Minolta 
T-10A). The average amount of lux at 20 cm of the lightboxes used 
in group I was 11,214 lux (range 10,860–11,640) and in group II 
was 317 lux (range 297–329). At a distance of 30 cm, the average 
amount of lux of lightboxes type I was 7,122 lux (range 6930–7380) 
and the average amount of lux of lightboxes type II was 198 lux 
(range 188–209). The Medical Technology Department checked 
all lightboxes used in this trial on safety. Physicians, psychologists 
and behavioural scientists were asked, but not obligated, not to 
make changes in (medication) treatment 4 weeks prior to enrol-
ment up to 6 weeks after the end of the intervention if this was not 
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considered necessary. Caregivers were asked to report changes in 
treatment during the study.
2.4.4 | Objectives and outcomes
The primary objective of this study was to examine whether BLT is 
effective in decreasing depressive symptoms in two BLT interven-
tion groups compared to no-BLT 1 week after the end of BLT. The 
Depressive Mood subscale (13 items) of the Anxiety, Depression And 
Mood Scale (ADAMS) was used to study these depressive symptoms 
prior to BLT (baseline, T0) and 1 week after BLT (T1) (Hamers, van 
Ool, et al., 2018; Hermans & Evenhuis, 2013; Hermans et al., 2012). 
The measurements in the control group (no-BLT) had the same fre-
quency. The Depressive Mood subscale of the ADAMS consists of 
the following 13 items: “Sleeps more,” “Depressed,” “Sad,” “Worried,” 
“Attention,” “Fatigued,” “Lacks energy,” “Distracted,” “Facial 
expression,” “Starting routine tasks,” “Listless,” “Trembles” and 
“Tearfull” (Hamers, van Ool, et al., 2018; Hermans & Evenhuis, 2013; 
Hermans et al., 2012).
Our secondary objectives were to examine whether there is 
a significant difference in effect of BLT between both interven-
tion groups. The ADAMS Depressive Mood subscale scores on 
T0 and T1 of group I and group II were used to investigate this 
objective. Further, we examined whether the effect of BLT is still 
visible 4 weeks after the end of the BLT intervention with use of 
the Dutch ADAMS Depression subscale scores of groups I and II 
at T0 and T2. Additionally, subgroup analyses were used to ex-
amine depressive symptoms in the three different groups on T1 
and T2.
In addition to the ADAMS Depressive Mood subscale, the Dutch 
Signalizing Depression List for people with Intellectual Disabilities 
(SDL-ID) (Roeden, 1989) was used to evaluate the effectiveness 
of BLT as well, because this measurement contains items that are 
F I G U R E  1   Flow diagram participants. *Professional caregiver did not complete the questionnaires at this time point. **No compliance to 
the study protocol
Assessed for eligibility (n = 120)
Excluded  (n = 79)
• Not enough depressive symptoms (n = 35)
• Declined to participate (legal guardian) (n = 19)
• Declined to participate (participant) (n = 5)
• Medical contra-indication (n = 13)
• Other reasons (n = 7)
Excluded from analysis (n = 0)
Analysed  T0-T1 (n = 11)
Analysed  T0-T2 (n = 12)
Lost to follow-up T1 (n = 1)*
Lost to follow-up T2 (n = 0)
Discontinued intervention (n = 0)  
Allocated to Group I (n = 12)
Received allocated intervention (n = 12)
Randomized (n = 41)
Allocated to Group II (n = 15)
Received allocated intervention (n = 15)
Allocated to Group III (n = 14)
Received allocated intervention (n = 14)
Lost to follow-up T1 (n = 1)*
Lost to follow-up T2 (n = 1)*
Discontinued intervention (n = 0)  
Lost to follow-up T1 (n = 0)
Lost to follow-up T2 (n = 0)
Discontinued intervention (n = 0)  
Excluded from analysis (n = 1)**
Analysed  T0-T1 (n = 13)
Analysed  T0-T2 (n = 13)
Excluded from analysis (n = 0)
Analysed  T0-T1 (n = 14)
Analysed  T0-T2 (n = 14)
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complementary to the Dutch ADAMS Depressive Mood subscale. 
Besides, a subscale of the Aberrant Behavior Checklist (ABC) (Aman, 
Singh, Stewart, & Field, 1985) was used to measure “Irritability,” be-
cause it is known that a large part of adults with intellectual disabil-
ities and depressive symptoms have symptoms of irritability. In the 
Netherlands, these measurements are often used in clinical practice 
to evaluate the effectiveness of interventions. The questionnaires 
were completed by a professional caregiver at T0, T1 and T2. ABC 
scores were only available on baseline.
The presence of a major depression disorder according to the 
criteria of DSM-IV was investigated with the PAS-ADD Clinical 
Interview, which is a semi-structured psychiatric interview de-
veloped for adults with intellectual disabilities (Moss, 2011). Prior 
to the start of the study, the participants (if possible) and the 
Group IBLT 10,000 
lux  
n = 12
Group II BLT dim 
light 
 n = 14
Group III 
Control group  
n = 14 p-valuea 
Sex
Male (%) 5 (41.7) 4 (28.6) 11 (78.6) .024
Female (%) 7 (58.3) 10 (71.4) 3 (21.4)
Age, years
Mean (SD) 56.17 (11.33) 57.14 (11.41) 52.07 (14.29) .531
Level of intellectual disabilities (%)
Mild 5 (41.7) 2 (14.3) 2 (14.3) .076
Moderate 2 (16.7) 2 (14.3) 8 (57.1)
Severe 3 (25.0) 7 (50.0) 2 (14.3)
Profound 2 (16.7) 3 (16.7) 2 (14.3)
Medication use (%)b 
Antidepressants 6 (50.0) 6 (42.9) 6 (42.9) .728
Antipsychotics 9 (75.0) 9 (64.3) 8 (57.1) .650
Benzodiazepines 4 (33.3) 5 (35.7) 3 (21.4) .653
Anti-epileptics 5 (41.7) 4 (28.6) 2 (14.3) .404
Contraception 2 (16.7) 2 (14.3) 1 (7.1) .665
Beta-blockers 1 (8.3) 0 (0.0) 1 (7.1) .540
Anxiolytics 0 (0.0) 0 (0.0) 0 (0.0) .386
Melatonin 0 (0.0) 1 (7.1) 0 (0.0) .440
No medication 
used
1 (8.3) 3 (21.4) 2 (14.3) .596
Missing data 0 (0.0) 0 (0.0) 1 (7.1)
ABC Irritability subscale
Mean (SD) 9.17 (4.49) 10.36 (7.62) 12.00 (6.45) .530
Total BLT days
Mean (SD) 13.00 (1.54) 12.14 (2.07) n.a. .249
Date of BLT intervention/control group period, n (%)
1st Quarter of the 
year
6 (50.0) 2 (14.3) 6 (42.9) .164
2nd Quarter of 
the year
4 (33.3) 4 (28.6) 4 (28.6)
3rd Quarter of the 
year
1 (8.3) 2 (14.3) 3 (21.4)
4th Quarter of the 
year
1 (8.3) 6 (42.9) 1 (7.1)
Abbreviations: ABC, the Aberrant Behavior Checklist; BLT, bright light therapy; ID, intellectual 
disability; n.a., not applicable; SD, standard deviation.
aCalculated as comparisons of the three groups, using ANOVA for continuous variables or chi-
square tests for discrete variables. The comparison of total BLT days was only calculated for the 
two intervention groups. 
bSome participants used more than 1 medication. Significant test values are in bold type. 
TA B L E  1   Participant characteristics
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professional caregivers of those in both BLT groups were asked to 
complete a questionnaire about the expectations of the BLT inter-
vention. Besides, the professional caregivers were asked to report 
compliance, adverse events and side effects in a daily log during 
the intervention. In case of a serious adverse event (SAE), such as 
hospitalizations, serious illness or death, professional caregivers 
were asked to report to the researchers immediately. We retrieved 
information on sex, age, level of intellectual disabilities, use of 
medication, residential setting, treatment during study interven-
tion and BLT in the past by participants’ medical and psychological 
files.
2.5 | Statistical analyses
Data were analysed using IBM SPSS Statistics 24. Prior to the start 
of the study, we stated in our study protocol that the intention-to-
treat basis shall be used. None of the participants assigned to one 
of the three study groups switched to another study arm. Missing 
data on T1 and T2 were not imputed but reported. Baseline char-
acteristics of the participants, baseline depression scores and 
baseline ABC Irritability scores were checked for any significant 
differences between the three groups. Expectations prior to the 
BLT, total amount of BLT days, compliance with the intervention 
Group I 10,000 
lux




ADAMS Depression subscale T0
Mean (SD) 21.83 (5.49) 19.86 (3.70) 19.43 (4.70)
ADAMS Depression subscale T1
Mean (SD) 13.73 (5.68)a  16.00 (6.92) 18.86 (7.38)
ADAMS Depression subscale Change T0-T1
Mean (95% CI) 8.36 (3.50 to 
13.23)b 
3.54 (0.82 to 6.26)b  0.57 (−3.91 to 
5.05)
Cohen's d effect size T0-T1 1.52 0.73 0.10
(95% CI) (−0.66 to 3.70) (−1.26 to 2.72) (−2.11 to 2.30)
ADAMS Depression subscale T2
Mean (SD) 11.25 (7.03)a  14.85 (7.70) 16.29 (8.42)
ADAMS Depression subscale Change T0-T2
Mean (95% CI) 10.58 (5.61 to 
15.55)b 
5.39 (2.13 to 8.64)b  3.14 (−1.62 to 
7.91)
Cohen's d effect size T0-T2 1.75 0.87 0.48
(95% CI) (−0.67 to 4.17) (−1.29 to 3.04) (−1.96 to 2.91)
SDL-ID total scores T0
Mean (SD) 38.17 (6.63) 39.29 (3.41) 37.57 (6.16)
SDL-ID total scores T1
Mean (SD) 30.82 (6.23)a  35.15 (6.14) 38.07 (7.98)
SDL-ID total scores Change T0-T1
Mean (95% CI) 8.00 (3.43 to 
12.57)b 
4.00 (0.060 to 7.94) −0.50 (−4.24 
to 3.24)
Cohen's d effect size T0-T1 1.19 0.88 −0.07
(95% CI) (−1.32 to 3.71) (−0.91 to 2.66) (−2.62 to 2.47)
SDL-ID total scores T2
Mean (SD) 29.33 (5.94)a  32.69 (6.03)a  35.50 (7.62)
SDL-ID total scores Change T0-T2
Mean (95% CI) 8.83 (3.35 to 
14.32)b 
6.85 (3.37 to 
10.33)b 
2.07 (−1.91 to 
6.06)
Cohen's d effect size T0-T2 1.47 1.42 0.31
(95% CI) (−0.95 to 3.88) (−0.35 to 3.17) (−2.16 to 2.78)
Note: T0: baseline, T1: 1 week after intervention, T2: 4-week follow-up. Clinical cut-off point 
ADAMS Depression subscale = 14. Clinical cut-off point SDL-ID total score = 35.
aMean score below clinical cut-off point. 
bSignificant difference (a significant level of p = .017 (0.05/3) was used to correct for increased risk 
of a type 1 error due to multiple comparisons). 
TA B L E  2   Outcomes ADAMS 
Depression subscale and SDL-ID total 
score
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and date of the intervention/control group period (quarter) were 
analysed with one-way ANOVA (2-sided) for continuous data and 
chi-squared tests for categorical data to check for confounders. 
Baseline differences between the groups were taken as a con-
founder into the analyses.
To investigate the effect of BLT on depressive symptoms, multi-
variate regression analyses were used. The ADAMS Depressive Mood 
subscale of group I and group II was compared separately with those 
of group III (control group). Independent-samples t tests were used 
to investigate whether there was a significant difference in effect of 
BLT between both intervention groups. Repeated-measures ANOVA 
was used to investigate the effect of BLT at follow-up (4 weeks after 
the end of BLT). For the subgroup analyses, paired-samples t tests 
were used to investigate the ADAMS Depression subscale scores on 
T1 and T2 in the three different study groups. A Bonferroni correc-
tion resulted in a significant level of p = .017 (0.05/3). A Bonferroni 
correction corrects for increased risk of a type 1 error due to mul-
tiple comparisons. Effect sizes were measured using Cohen's d. All 




Between May 2015 and September 2017, 41 participants were in-
cluded in our trial. Twelve participants were randomly assigned to 
group I, 15 participants to group II and 14 participants to group III. 
Figure 1 shows the flow diagram of our study. One participant of 
group II was excluded after the intervention, because there was no 
compliance to the study protocol (14 days of BLT were given in a 
6-week period, instead of in a 2-week period). The characteristics 
of the participants of the three groups are presented in Table 1. The 
participants were aged between 24 and 81 years, and all levels of in-
tellectual disabilities were covered in this study. According to norms 
of Zeilinger, Weber, and Haveman (2011), 60.0% of our total sample 
had an ABC Irritability percentile ranking score above 80% (Zeilinger 
et al., 2011), which means these participants had a considerable 
amount of challenging behaviour.
On baseline, there were significant differences in “sex” between 
the three groups (p = .024) and we corrected for this baseline differ-
ence as appropriate. Expectations prior to the BLT (p = .056), total 
amount of BLT days (p = .060), compliance with the intervention 
(p = .420) and date of the intervention/control group period (quarter 
of the year) (p = .058) were checked for the possibility of influenc-
ing the T1 depression scores. None of these variables were con-
founders. At baseline, none of the participants was classified with a 
major depressive disorder. There were no significant differences be-
tween the three groups on baseline ADAMS depressive symptoms 
(p = .390) and SDL-ID total score (p = .709).
3.2 | Primary outcomes
Table 2 shows the clinical outcomes on depressive symptoms meas-
ured on baseline (T0), 1 week after the intervention (T1) and 4 weeks 
after the end of the intervention (T2). The multivariate regression 
analyses showed no significant differences between groups I and 
III on depressive symptoms measured with the ADAMS Depression 
subscale on T1 (p = .199) and no significant differences between 
group II and group III on T1 (p = .451).
3.3 | Secondary outcomes
Independent-samples t test revealed no significant differences 
between group I T1 and group II T1 ADAMS Depression subscale 
scores (p = .394). Likewise, there were no significant differences be-
tween group I T1 and group II T1 SDL-ID scores (p = .101). Repeated-
measures ANOVA was used to examine whether the effect of BLT 
was still visible 4 weeks after the end of BLT. We used the ADAMS 
Depression subscale scores at time 1 (baseline, T0), time 2 (1 week 
after BLT, T1) and time 3 (4-week follow-up, T2). In group I, Mauchly's 
F I G U R E  2   Mean change in ADAMS 
Depression subscale score (13 items) in 
patients randomly assigned to one of the 




























Group I (10.000 lux)
Group II (Dim light)
Group III (Control
group)
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test, χ2(2) = 4.70, p = .095, did not indicate any violation of sphericity. 
There was a significant effect for time in this group (p = .008). Post 
hoc tests using the Bonferroni correction for multiple comparisons 
revealed significant differences on ADAMS Depression subscale 
scores between time 1 and time 3 in group I (p = .004). In group 
II, Mauchly's test, χ2(2) = 1.72, p = .423, did not indicate any viola-
tion of sphericity and there was a significant effect for time as well 
(p = .013). Post hoc tests using the Bonferroni correction showed 
significant differences between time 1 and time 3 (p = .008) in this 
group.
The results of the subgroup analyses (paired-samples t tests) 
including the effect sizes measured with Cohen's d can be found 
in Table 2. In group I, we found a significant difference with 
a very large effect size (d = 1.52) between T0 and T1 ADAMS 
Depression subscale scores (p = .003). We also found a signifi-
cant difference with a very large effect size (d = 1.75) between T0 
and T2 ADAMS Depression subscale scores in group I (p = .001). 
In group II, a significant difference with a medium effect size 
(d = 0.73) was found between T0 and T1 ADAMS Depression 
subscale scores (p = .015). Furthermore, we found a significant 
difference with a large effect size (d = 0.87) between T0 and T2 
ADAMS Depression subscale scores (p = .004). In group III, no 
significant differences were found between T0 and T1 ADAMS 
Depression subscale scores (p = .787). Likewise, we found no 
TA B L E  3   Participant characteristics (n = 36)
Group I BLT 10,000 lux 
n = 11
Group II BLT dim light 
n = 11





Male (%) 4 (36.4) 3 (27.3) 11 (78.6) .022
Female (%) 7 (63.6) 8 (72.7) 3 (21.4)
Age, years
Mean (SD) 57.64 (10.61) 58.82 (9.72) 52.07 (14.29) .408
Level of intellectual disabilities (%)
Mild 5 (45.5) 1 (9.1) 2 (14.3) .026
Moderate 2 (18.2) 1 (9.1) 8 (57.1)
Severe 3 (27.3) 7 (63.6) 2 (14.3)
Profound 1 (9.1) 2 (18.2) 2 (14.3)
Medication use (%)b 
Antidepressants 6 (54.5) 5 (45.5) 6 (42.9) .763
Antipsychotics 8 (72.7) 6 (54.5) 8 (57.1) .657
Benzodiazepines 4 (36.4) 5 (45.5) 3 (21.4) .565
Anti-epileptics 4 (36.4) 3 (27.3) 2 (14.3) .558
Contraception 2 (18.2) 1 (9.1) 1 (7.1) .670
Beta-blockers 1 (9.1) 0 (0.0) 1 (7.1) .621
Anxiolytics 0 (0.0) 0 (0.0) 0 (0.0) .446
Melatonin 0 (0.0) 1 (9.1) 0 (0.0) .420
No medication used 1 (9.1) 3 (27.3) 2 (14.3) .516
Missing data 0 (0.0) 0 (0.0) 1 (7.1)
ABC Irritability subscale
Mean (SD) 8.64 (4.30) 12.00 (7.64) 12.00 (6.45) .473
Total BLT days
Mean (SD) 13.36 (0.92) 13.09 (0.94) n.a. .501
Date of BLT intervention/control group period, n (%)
1st Quarter of the year 6 (54.5) 2 (18.2) 6 (42.9) .026
2nd Quarter of the year 4 (36.4) 3 (27.3) 4 (28.6)
3rd Quarter of the year 0 (0.0) 0 (0.0) 3 (21.4)
4th Quarter of the year 1 (9.1) 6 (54.5) 1 (7.1)
Abbreviations: ABC, the Aberrant Behavior Checklist; BLT, bright light therapy; ID, intellectual disability; n.a., not applicable; SD, standard deviation.
aCalculated as comparisons of the three groups, using ANOVA for continuous variables or chi-square tests for discrete variables. The comparison of 
total BLT days was only calculated for the two intervention groups. 
bSome participants used more than 1 medication. Significant test values are in bold type. 
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significant differences between T0 and T2 ADAMS Depression 
subscale scores (p = .178). Table 2 also shows the subgroup anal-
yses with paired-samples t tests of the SDL-ID scores and the 
effect sizes measured with Cohen's d.
Figure 2 shows the mean change in ADAMS Depression subscale 
scores over time in the three groups. In group I, the mean ADAMS 
Depression subscale score and the mean SDL-ID score on T1 and 
T2 decreased below the clinical cut-off points. In group II, only the 
mean SDL-ID score on T2 was below the clinical cut-off point. In 
group III, no mean scores on T1 and T2 decreased below the clinical 
cut-off points.
In group I, 75.0% of the participants had a decreased ADAMS 
Depression subscale score on T1. In group II and group III, this 
was 71.4% and 57.1%, respectively. When further examined, 
the depression scores of 45.5% of the participants in group I 
and 7.7% of the participants in group II were decreased 40% or 
more after BLT. In group III, 14.3% of the participants had 40% 
or more decreased depression scores after their control group 
period.
The multivariate regression analyses with the SDL-ID scores on 
T1 showed significant differences between group I and group III 
(p = .046). It was found that “group” significantly predicted the T1 
Group I 10,000 
lux




ADAMS Depression subscale T0
Mean (SD) 22.36 (5.43) 19.36 (3.64) 19.43 (4.70)
ADAMS Depression subscale T1
Mean (SD) 13.60 (5.97)a  15.45 (7.44) 18.86 (7.38)
ADAMS Depression subscale Change T0-T1
Mean (95% CI) 9.10 (3.96 to 
14.24)b 
3.91 (0.84 to 6.98) 0.57 (−3.91 to 
5.05)
Cohen's d effect size T0-T1 1.62 0.70 0.10
(95% CI) (−0.70 to 3.93) (−1.63 to 3.03) (−2.11 to 2.30)
ADAMS Depression subscale T2
Mean (SD) 11.91 (6.98)a  14.10 (8.08) 16.29 (8.42)
ADAMS Depression subscale Change T0-T2
Mean (95% CI) 10.46 (4.95 to 
15.96)b 
5.70 (1.57 to 9.83)b  3.14 (−1.62 to 
7.91)
Cohen's d effect size T0-T2 1.75 0.88 0.48
(95% CI) (−0.74 to 4.24) (−1.62 to 3.38) (−1.96 to 2.91)
SDL-ID total scores T0
Mean (SD) 38.55 (6.82) 39.36 (3.70) 37.57 (6.16)
SDL-ID total scores T1
Mean (SD) 30.90 (5.56)a  35.73 (6.53) 38.07 (7.98)
SDL-ID total scores Change T0-T1
Mean (95% CI) 8.40 (3.37 to 
13.43)b 
3.64 (−1.11 to 8.38) −0.50 (−4.24 
to 3.24)
Cohen's d effect size T0-T1 1.20 0.72 −0.07
(95% CI) (−1.52 to 3.93) (−1.40 to 2.83) (−2.62 to 2.47)
SDL-ID total scores T2
Mean (SD) 30.00 (5.75)a  33.10 (6.19)a  35.50 (7.62)
SDL-ID total scores Change T0-T2
Mean (95% CI) 8.55 (2.50 to 
14.59)b 
6.60 (2.07 to 
11.13)b 
2.07 (−1.91 to 
6.06)
Cohen's d effect size T0-T2 1.42 1.31 0.31
(95% CI) (−1.09 to 3.93) (−0.74 to 3.36) (−2.16 to 2.78)
Note: T0: baseline, T1: 1 week after intervention, T2: 4-week follow-up. Clinical cut-off point 
ADAMS Depression subscale = 14. Clinical cut-off point SDL-ID total score = 35.
aMean score below clinical cut-off point. 
bSignificant difference (a significant level of p = .017 (0.05/3) was used to correct for increased risk 
of a type 1 error due to multiple comparisons). 
TA B L E  4   Outcomes ADAMS 
Depression subscale and SDL-ID (n = 36)
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SDL-ID scores (p = .014). There were no significant differences on T1 
SDL-ID scores between group II and group III (p = .401).
After the analyses for the whole sample (n = 40), we checked 
whether BLT with <10 days (in a period of 14 days) influenced 
the outcomes. Therefore, we repeated all analyses in a sample 
excluding the participants who had <10 BLT days in the 14-day 
period. In total, one participants of group I and three participants 
of group II were excluded for these sample analyses (n = 36). The 
patient characteristics of this sample can be found in Table 3, and 
depression outcomes of this sample can be found in Table 4. In 
this sample, we did not find significant differences between the 
BLT groups and control group or between both BLT groups on our 
primary outcome measure.
3.4 | Adverse events and side effects
No serious adverse events or adverse events were reported during 
this trial. A minimum amount of side effects were registered in the 
daily logs. Headache was reported twice in group II, and fatigue or 
drowsiness was mentioned three times in group I and once in group 
II. In the daily logs, other striking behaviour regarding the BLT was 
reported as well: some participants turned away their face or body 
from the lightbox. In group I, this was reported four times and in 
group II six times.
4  | DISCUSSION
Non-pharmacological treatment options for adults with intellectual 
disabilities and depressive symptoms are limited. As far as we know, 
this is the first multicentre randomized controlled trial investigating 
the effect of BLT on depressive symptoms in adults with intellectual 
disabilities. We found no significant effect between the three trial 
groups on our primary outcome. However, the results of our second-
ary analyses suggest that BLT with 10,000 lux decreases depressive 
symptoms directly after the intervention period and at follow-up, 
showing very large effect sizes. In the dim light group, there are also 
significant decreases in depressive symptoms directly after the in-
tervention and at follow-up with medium to large effect sizes. We 
did not find significant decrease of depressive symptoms in our con-
trol group.
Prior to the current study, only a couple of case reports (Altabet 
et al., 2002; Cooke & Thompson, 1998; Tsiouris, 2007) and one 
feasibility study (Hermans et al., 2017) were published on BLT 
for adults with intellectual disabilities and depressive symptoms. 
Positive results were found in these first explorations of BLT to 
decrease depressive symptoms in adults with intellectual disabil-
ities, but these must be interpreted with caution because of the 
lack of a randomization procedure and control groups. Therefore, 
the strengths of the current study, for example the block random-
ization and blinding procedures, and the strictly protocolled in-
tervention, make this study adding important information to the 
existing literature (Hamers, Festen, et al., 2018). As most studies, 
our study has a couple of limitations which must be mentioned. 
The first limitation is the small sample size of the three groups. 
During our study, we faced a number of obstacles (Hamers 
et al., 2017). From the 120 potential participants who were signed 
up for the study, only 41 could be included in our trial. The strict 
inclusion criteria of our trial, for example the exclusion of people 
with bipolar disorder and people who use specific photosensitizing 
medications, contributed to the safety of our trial, but also low-
ered the number of participants enrolled in our study. With our 
small sample size, significant differences between the interven-
tion groups and the control group, and between both intervention 
groups may be hard to find, due to a lack of power. The confidence 
intervals of the mean change between baseline and T1 and be-
tween baseline and T2 in group I suggest that in a larger sample, 
it is likely that significant differences could be found. The second 
limitation of our study is the high prevalence of psychotropic med-
ication used in all three groups. Consequently, the BLT interven-
tion in this study cannot completely be seen as a monotherapy, 
but more as an add-on treatment. Since it is known that in the 
population of adults with intellectual disabilities (and depressive 
symptoms), high numbers of psychotropic medication are used, 
our sample seems quite representative.
It is interesting to note that in our study, antipsychotics are 
used more frequently than antidepressants, which was quite un-
expected because exclusion criteria of our study prevented in-
cluding participants with psychotic symptoms or bipolar disorder. 
Furthermore, in our sample, antipsychotics are used more often 
than in samples of adults with intellectual disabilities without 
depressive symptoms. From existing literature, we know that a 
large part of adults with intellectual disabilities use antipsychot-
ics off-label for challenging behaviour (de Kuijper et al., 2010). It 
is possible that in our study, a large part of the participants who 
use antipsychotics have depressive symptoms which are being ex-
pressed with challenging behaviour (also regarding the high scores 
on the ABC Irritability subscale at baseline), and therefore treated 
with off-label antipsychotics. Further, negative symptoms caused 
by antipsychotic medications, such as apathy, the incapability to 
show emotions or social withdrawal, can be rated by the caregiv-
ers as depressive symptoms, and hereby increase the depression 
score.
Except for a significant difference in depressive symptoms be-
tween group I and group III after the intervention measured with 
one questionnaire in our secondary outcomes, we did not find any 
significant differences in depressive symptoms between the 10,000 
lux condition, dim light condition and care as usual. However, we did 
find that half of the participants recovered for at least 40% from their 
depressive symptoms after 10,000 lux BLT and <15% recovered for 
at least 40% after dim light BLT or no-BLT (control group). Overall, 
we do see a positive trend in decreasing depressive symptoms in our 
10,000 lux BLT group, with the number of depressive symptoms even 
beneath the clinical cut-off points after the intervention. This makes 
BLT a promising intervention to decrease depressive symptoms in 
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clinical practice. Therefore, RCTs with larger sample sizes (also with 
and without used psychotropic medication) are needed to further in-
vestigate the (direct) effect of BLT on depressive symptoms of adults 
with intellectual disabilities.
In summary, to the best of our knowledge, this is the first multi-
centre RCT investigating the effect of BLT on depressive symptoms 
in adults with intellectual disabilities. Our results show significant de-
creases of depressive symptoms in both intervention groups, but not 
in the control group. Overall, significant differences between both in-
tervention groups, and between the intervention groups and control 
group were not found, which is possibly due to a sample size prob-
lem. Trial replications with larger samples are needed. Compared to 
psychotropic medication, BLT has limited side effects, is not expen-
sive and can have immediate effect after a short period. This makes 
BLT a promising non-pharmacological treatment option to decrease 
depressive symptoms in adults with intellectual disabilities.
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